Company Overview and News

0
0
HZNP vs. LGND: Which Stock Is the Better Value Option?

2018-07-10 zacks
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Horizon Pharma (HZNP - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
LGNZZ LGND LGNYZ LGNXZ HZNP LGNDZ

109
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal

2018-07-01 seekingalpha
CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios (NASDAQ:AGIO), a Boston area pharma, in a deal worth up to $424 million (see story). CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia (AML) and cholangiocarcinoma, although the companies believe ivosidenib has potential efficacy against many cancer indications including glioma.
PCRX ZLAB LGND AGIO ONCYF AMRS NVS ONC ONCY BEAV WXXWY ONCYD

2
48
Is Exelixis A Better Biotech Stock Than Ligand Pharmaceuticals?

2018-06-25 seekingalpha
But your portfolio’s value grows by what other investors (including big$ ones) is willing to pay for the.
EXEL GILD LGND CBM

48
Is Excelixis A Better Biotech Stock Than Ligand Pharmaceuticals?

2018-06-25 seekingalpha
But your portfolio’s value grows by what other investors (including big$ ones) is willing to pay for the.
EXEL GILD LGND CBM

3
37
3 Biotech Stocks Up in the Past Month on Industry Turnaround

2018-06-15 investorplace
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
VVUS GLENMARK 532296 LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY

25
Viking Therapeutics: What Now After 'Yuge' Rally?

2018-06-12 seekingalpha
The stock has nearly quadrupled over the past nine months, is there still more potential upside ahead?
MDGL VKTXW LGNZZ LGNYZ LGND LGNXZ VKTX LGNDZ

49
3 Biotech Stocks Up in the Past Month on Industry Turnaround

2018-06-05 zacks
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
VVUS GLENMARK DB 532296 JNJ LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY

84
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

2018-06-04 zacks
Chicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Illumina, Inc. (ILMN - Free Report) , Athersys, Inc. (ATHX - Free Report) , EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) , Rhythm Pharmaceuticals, Inc.
NTLA EYPT UAA JBLU ILMN RYTM LGNDZ UA BRK.A ATHX LGNZZ LGND LGNYZ DG LGNXZ

2
LGND / Ligand Pharmaceuticals Incorporated DEFA14A

2018-06-04 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule
LGND

23
Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up

2018-06-01 zacks
Kitov Pharma Ltd. (KTOV - Free Report) announced today that the FDA has approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
LGNZZ LGND LGNYZ LGNXZ HZNP PFE LGNDZ

95
Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

2018-05-31 zacks
Shares of Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) rose almost 8.2%, after the company announced that the FDA has accepted the new drug application (NDA) for its lead pipeline candidate, Firdapse, and granted Priority Review to the same. The FDA has set an action date of Nov 28, 2018.
CPRX ELY LGNZZ LGND LGNYZ LGNXZ ILMN LGNDZ BMRN

12
MLNT / Melinta Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-31 fintel.io
Melinta Therapeutics, Inc. (NASDAQ:MLNT) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,653,082 shares. Largest shareholders include Vatera Holdings Llc, Chelsea Counsel Co, Commonwealth Equity Services, Inc, Group One Trading, L.p., and Group One Trading, L.p.. Melinta Therapeutics, Inc.
LGNZZ LGNYZ LGND FH LGNXZ MLNT LGNDZ XSPA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to LGND / Ligand Pharmaceuticals Incorporated on message board site Silicon Investor.

Ligand (LGND) Breakout! LGND: Ligand Pharmaceuticals
Ligand - LGND - thread for non-PhDs Ligand Pharmaceuticals (LGND)
CUSIP: 53220K504